GlobeNewswire: Alcobra Ltd. Contains the last 10 of 128 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T11:58:41ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2017/11/09/1178477/0/en/Alcobra-Announces-Third-Quarter-2017-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=19283Alcobra Announces Third Quarter 2017 Financial Results and Provides Corporate Update2017-11-09T12:00:00Z<![CDATA[TEL AVIV, Israel, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD) today announced financial results for the three and nine months ended September 30, 2017, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2017/08/11/1083723/0/en/Alcobra-Announces-Second-Quarter-2017-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=19283Alcobra Announces Second Quarter 2017 Financial Results and Provides Corporate Update2017-08-11T12:00:00Z<![CDATA[TEL AVIV, Israel, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) today announced financial results for the three and six months ended June 30, 2017, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2017/06/23/1028391/0/en/Alcobra-Updates-on-its-Review-of-Strategic-Alternatives.html?f=22&fvtc=4&fvtv=19283Alcobra Updates on its Review of Strategic Alternatives2017-06-23T11:00:00Z<![CDATA[TEL AVIV, Israel, June 23, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that its Board of Directors is conducting a process to explore and review a range of strategic alternatives focused on maximizing stockholder value from its development assets and cash resources. Alcobra has engaged Ladenburg Thalmann & Co. Inc. to act as its strategic financial advisor for this process. In conjunction with the exploration of strategic alternatives, the Company also intends to streamline its operations in order to preserve its capital and cash resources.]]>https://www.globenewswire.com/news-release/2017/06/12/1017736/0/en/Alcobra-Announces-Cooperation-Agreement-with-Brosh-Group-and-Board-Additions.html?f=22&fvtc=4&fvtv=19283Alcobra Announces Cooperation Agreement with Brosh Group and Board Additions2017-06-12T12:36:13Z<![CDATA[Company Adds Two Directors to the Board]]>https://www.globenewswire.com/news-release/2017/05/30/999888/0/en/Alcobra-Announces-First-Quarter-2017-Financial-Results-and-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=19283Alcobra Announces First Quarter 2017 Financial Results and Provides Corporate Update2017-05-30T12:00:00Z<![CDATA[TEL AVIV, Israel, May 30, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD) today announced financial results for the three months ended March 31, 2017, and provided a corporate update.]]>https://www.globenewswire.com/news-release/2017/05/15/984811/0/en/Alcobra-Announces-Leadership-Update.html?f=22&fvtc=4&fvtv=19283Alcobra Announces Leadership Update2017-05-15T12:00:00Z<![CDATA[Dr. Yaron Daniely to Step Down as Chief Executive Officer, Effective May 31, 2017]]>https://www.globenewswire.com/news-release/2017/05/05/979722/0/en/Alcobra-Provides-Update-on-Cancellation-of-Extraordinary-Meeting-Called-by-Brosh-Group.html?f=22&fvtc=4&fvtv=19283Alcobra Provides Update on Cancellation of Extraordinary Meeting Called by Brosh Group2017-05-05T16:42:49Z<![CDATA[TEL AVIV, Israel, May 05, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat significant unmet clinical needs, today announced that it has reached an agreement (the “Agreement") with Brosh Capital L.P. and certain of its affiliates (the “Brosh Group") on the cancellation of the Extraordinary General Meeting of Shareholders previously called by the Brosh Group to be held on May 23, 2017 (the “Extraordinary General Meeting”).]]>https://www.globenewswire.com/news-release/2017/04/24/970126/0/en/Alcobra-Mails-Proxy-Materials-for-Extraordinary-General-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=19283Alcobra Mails Proxy Materials for Extraordinary General Meeting of Shareholders2017-04-24T10:00:00Z<![CDATA[The Board Will Defend Shareholders from Opportunistic Takeover of the Company]]>https://www.globenewswire.com/news-release/2017/04/05/954681/0/en/Alcobra-Provides-Update-on-Request-for-Extraordinary-General-Meeting.html?f=22&fvtc=4&fvtv=19283Alcobra Provides Update on Request for Extraordinary General Meeting2017-04-05T12:00:00Z<![CDATA[Brosh Capital’s Request Does Not Comply With Alcobra’s Articles of Association]]>https://www.globenewswire.com/news-release/2017/03/07/932803/0/en/Alcobra-Ltd-to-Participate-in-Upcoming-Healthcare-Conferences.html?f=22&fvtc=4&fvtv=19283Alcobra Ltd. to Participate in Upcoming Healthcare Conferences2017-03-07T13:00:00Z<![CDATA[TEL AVIV, Israel, March 07, 2017 (GLOBE NEWSWIRE) -- Alcobra Ltd. (NasdaqGM:ADHD), an emerging pharmaceutical company focused on the development of new medications to treat central nervous system and cognitive disorders, today announced that management will participate in two upcoming investor healthcare conferences during March.]]>